Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition-Reference-Cited by-同舟云学术

Activated Blood Coagulation Factor X (FXa) Contributes to the Development of Traumatic PVR Through Promoting RPE Epithelial-Mesenchymal Transition

Published:2021-07-20 Issue:9 Volume:62 Page:29
ISSN:1552-5783
Container-title:Investigative Opthalmology & Visual Science
language:en
Short-container-title:Invest. Ophthalmol. Vis. Sci.

Author:

Han Han¹,Zhao Xiao¹,Liao Mengyu¹,Song Yinting¹,You Caiyun¹,Dong Xue¹²,Yang Xueli¹³,Wang Xiaohong²,Huang Bo⁴,Du Mei²,Yan Hua¹

Affiliation:

1. Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China

2. Laboratory of Molecular Ophthalmology, Department of Pharmacology and Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

3. Department of Ophthalmology, The First Affiliated Hospital of Dali University, Yunnan, China

4. Department of Ophthalmology, University of Mississippi Medical Center, Jackson, Mississippi, United States

Publisher

Association for Research in Vision and Ophthalmology (ARVO)

Subject

General Medicine

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-omics profiling of retinal pigment epithelium reveals enhancer-driven activation of RANK-NFATc1 signaling in traumatic proliferative vitreoretinopathy;Nature Communications;2024-08-25

2. Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway;International Journal of Ophthalmology;2024-06-18

3. ABCA4 mediated traumatic proliferative vitreoretinopathy associated with PI3K/Akt signaling pathway;Heliyon;2024-04

4. Nintedanib inhibits normal human vitreous-induced epithelial-mesenchymal transition in human retinal pigment epithelial cells;Biomedicine & Pharmacotherapy;2023-10

5. In vitro laboratory models of proliferative vitreoretinopathy;Survey of Ophthalmology;2023-09